Fresenius Kabi
Fabian Fischer currently serves as Senior Director of Controlling and Consolidation for the Business Unit Pharma at Fresenius Kabi, a role commenced in April 2023. Previously, Fabian held multiple positions within Fresenius Kabi, including Director of Controlling and Consolidation for both the Business Unit Pharma and the Generics & I.V. Fluids EU & RoW segments. Prior to joining Fresenius Kabi, Fabian was part of Fresenius Digital Technology, where responsibilities included Director of Financial Planning, Analysis & Reporting, Senior Manager of Controlling, Controller, and Trainee in Finance & Controlling, starting in August 2015.
This person is not in any teams
This person is not in any offices
Fresenius Kabi
16 followers
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.